Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2 - Tabular View

Tracking Information

First Received Date ^ICMJE

September 8, 2006

Last Updated Date

July 31, 2007

Start Date ^ICMJE

August 2006

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Headache

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00374530 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

rCBF, blood flow, diameter of STA/RA, HR, BP

Original Secondary Outcome Measures ^ICMJE

Same as current

Descriptive Information

Brief Title ^ICMJE

Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2

Official Title ^ICMJE

Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2

Brief Summary

Before, during and after intravenous administration of PGE2 we score/measure headache, rCBF, blood flow in the middle cerebral artery and diameter of superficial temporal artery and correlate that to known pathophysiology of headache to see if PGE2 is involved in headache pathophysiology.

Detailed Description

Study Phase

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Randomized, Double-Blind, Placebo Control, Crossover Assignment

Condition ^ICMJE

Headache
Migraine

Intervention ^ICMJE

Drug: PGE2

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Estimated Enrollment ^ICMJE

Completion Date

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Healthy volunteers

Exclusion Criteria:

Primary Headache, headache on the day of the investigation, hypertension, hypotension, pregnant/nursing, daily intake of medication (except oral contraceptives), Cardiovascular or CNS disease, drug/alcohol abuse, psychiatric disease

Gender

Both

Ages

18 Years to 40 Years

Accepts Healthy Volunteers

Yes

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Denmark

Administrative Information

NCT ID ^ICMJE

NCT00374530

Responsible Party

Study ID Numbers ^ICMJE

KA-20060026

Study Sponsor ^ICMJE

Danish Headache Center

Collaborators ^ICMJE

Investigators ^ICMJE

Principal Investigator:

Troels Wienecke, MD

Danish Headache Center

Information Provided By

Danish Headache Center

Verification Date

July 2007

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP